HIV-1-neutralizing IgA detected in genital secretions of highly HIV-1-exposed seronegative women on oral preexposure prophylaxis

for the Partners PrEP Study

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although nonhuman primate studies have shown that simian immunodeficiency virus/simian-human immunodeficiency virus (SIV/SHIV) exposure during preexposure prophylaxis (PrEP) with oral tenofovir can induce SIV immunity without productive infection, this has not been documented in humans. We evaluated cervicovaginal IgA in Partners PrEP Study participants using a subtype C primary isolate and found that women on PrEP had IgA with higher average human immunodeficiency virus type 1 (HIV-1)-neutralizing magnitude than women on placebo (33% versus 7%; P = 0.008). Using a cutoff of ≥90% HIV-1 neutralization, 19% of women on-PrEP had HIV-1-neutralizing IgA compared to 0% of women on placebo (P = 0.09). We also estimated HIV-1 exposure and found that the proportion of women with HIV-1-neutralizing IgA was associated with the level of HIV-1 exposure (P = 0.04). Taken together, our data suggest that PrEP and high levels of exposure to HIV may each enhance mucosal HIV-1-specific humoral immune responses in sexually exposed but HIV-1-uninfected individuals.

Original languageEnglish (US)
Pages (from-to)9855-9861
Number of pages7
JournalJournal of Virology
Volume90
Issue number21
DOIs
StatePublished - 2016

Fingerprint

Human immunodeficiency virus 1
neutralization
Immunoglobulin A
genitalia
HIV-1
mouth
disease control
secretion
Simian Immunodeficiency Virus
Tenofovir
placebos
Placebos
HIV
Simian immunodeficiency virus
Human immunodeficiency virus
Humoral Immunity
humoral immunity
Primates
Immunity
immunity

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

HIV-1-neutralizing IgA detected in genital secretions of highly HIV-1-exposed seronegative women on oral preexposure prophylaxis. / for the Partners PrEP Study.

In: Journal of Virology, Vol. 90, No. 21, 2016, p. 9855-9861.

Research output: Contribution to journalArticle

@article{1e102b6304614392952dd6179df5155e,
title = "HIV-1-neutralizing IgA detected in genital secretions of highly HIV-1-exposed seronegative women on oral preexposure prophylaxis",
abstract = "Although nonhuman primate studies have shown that simian immunodeficiency virus/simian-human immunodeficiency virus (SIV/SHIV) exposure during preexposure prophylaxis (PrEP) with oral tenofovir can induce SIV immunity without productive infection, this has not been documented in humans. We evaluated cervicovaginal IgA in Partners PrEP Study participants using a subtype C primary isolate and found that women on PrEP had IgA with higher average human immunodeficiency virus type 1 (HIV-1)-neutralizing magnitude than women on placebo (33{\%} versus 7{\%}; P = 0.008). Using a cutoff of ≥90{\%} HIV-1 neutralization, 19{\%} of women on-PrEP had HIV-1-neutralizing IgA compared to 0{\%} of women on placebo (P = 0.09). We also estimated HIV-1 exposure and found that the proportion of women with HIV-1-neutralizing IgA was associated with the level of HIV-1 exposure (P = 0.04). Taken together, our data suggest that PrEP and high levels of exposure to HIV may each enhance mucosal HIV-1-specific humoral immune responses in sexually exposed but HIV-1-uninfected individuals.",
author = "{for the Partners PrEP Study} and Lund, {Jennifer M.} and Kristina Broliden and Pyra, {Maria N.} and Thomas, {Katherine K.} and Deborah Donnell and Elizabeth Irungu and Muwonge, {Timothy R.} and Nelly Mugo and Madhuri Manohar and Marianne Jansson and Romel Mackelprang and Marzinke, {Mark A.} and Baeten, {Jared M.} and Lingappa, {Jairam R.} and Connie Celum and Coombs, {Robert W.} and Lisa Frenkel and Hendrix, {Craig W.} and McElrath, {M. Juliana} and Kenneth Fife and Edwin Were and Elioda Tumwesigye and Patrick Ndase and Elly Katabira and Allan Ronald and Elizabeth Bukusi and Craig Cohen and Jonathan Wangisi and James Campbell and Jordan Tappero and James Kiarie and Carey Farquhar and Grace John-Stewart and Mugo, {Nelly Rwamba}",
year = "2016",
doi = "10.1128/JVI.01482-16",
language = "English (US)",
volume = "90",
pages = "9855--9861",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "21",

}

TY - JOUR

T1 - HIV-1-neutralizing IgA detected in genital secretions of highly HIV-1-exposed seronegative women on oral preexposure prophylaxis

AU - for the Partners PrEP Study

AU - Lund, Jennifer M.

AU - Broliden, Kristina

AU - Pyra, Maria N.

AU - Thomas, Katherine K.

AU - Donnell, Deborah

AU - Irungu, Elizabeth

AU - Muwonge, Timothy R.

AU - Mugo, Nelly

AU - Manohar, Madhuri

AU - Jansson, Marianne

AU - Mackelprang, Romel

AU - Marzinke, Mark A.

AU - Baeten, Jared M.

AU - Lingappa, Jairam R.

AU - Celum, Connie

AU - Coombs, Robert W.

AU - Frenkel, Lisa

AU - Hendrix, Craig W.

AU - McElrath, M. Juliana

AU - Fife, Kenneth

AU - Were, Edwin

AU - Tumwesigye, Elioda

AU - Ndase, Patrick

AU - Katabira, Elly

AU - Ronald, Allan

AU - Bukusi, Elizabeth

AU - Cohen, Craig

AU - Wangisi, Jonathan

AU - Campbell, James

AU - Tappero, Jordan

AU - Kiarie, James

AU - Farquhar, Carey

AU - John-Stewart, Grace

AU - Mugo, Nelly Rwamba

PY - 2016

Y1 - 2016

N2 - Although nonhuman primate studies have shown that simian immunodeficiency virus/simian-human immunodeficiency virus (SIV/SHIV) exposure during preexposure prophylaxis (PrEP) with oral tenofovir can induce SIV immunity without productive infection, this has not been documented in humans. We evaluated cervicovaginal IgA in Partners PrEP Study participants using a subtype C primary isolate and found that women on PrEP had IgA with higher average human immunodeficiency virus type 1 (HIV-1)-neutralizing magnitude than women on placebo (33% versus 7%; P = 0.008). Using a cutoff of ≥90% HIV-1 neutralization, 19% of women on-PrEP had HIV-1-neutralizing IgA compared to 0% of women on placebo (P = 0.09). We also estimated HIV-1 exposure and found that the proportion of women with HIV-1-neutralizing IgA was associated with the level of HIV-1 exposure (P = 0.04). Taken together, our data suggest that PrEP and high levels of exposure to HIV may each enhance mucosal HIV-1-specific humoral immune responses in sexually exposed but HIV-1-uninfected individuals.

AB - Although nonhuman primate studies have shown that simian immunodeficiency virus/simian-human immunodeficiency virus (SIV/SHIV) exposure during preexposure prophylaxis (PrEP) with oral tenofovir can induce SIV immunity without productive infection, this has not been documented in humans. We evaluated cervicovaginal IgA in Partners PrEP Study participants using a subtype C primary isolate and found that women on PrEP had IgA with higher average human immunodeficiency virus type 1 (HIV-1)-neutralizing magnitude than women on placebo (33% versus 7%; P = 0.008). Using a cutoff of ≥90% HIV-1 neutralization, 19% of women on-PrEP had HIV-1-neutralizing IgA compared to 0% of women on placebo (P = 0.09). We also estimated HIV-1 exposure and found that the proportion of women with HIV-1-neutralizing IgA was associated with the level of HIV-1 exposure (P = 0.04). Taken together, our data suggest that PrEP and high levels of exposure to HIV may each enhance mucosal HIV-1-specific humoral immune responses in sexually exposed but HIV-1-uninfected individuals.

UR - http://www.scopus.com/inward/record.url?scp=84994060602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994060602&partnerID=8YFLogxK

U2 - 10.1128/JVI.01482-16

DO - 10.1128/JVI.01482-16

M3 - Article

C2 - 27558421

AN - SCOPUS:84994060602

VL - 90

SP - 9855

EP - 9861

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 21

ER -